About 7 results found for searched term "88-15-3" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M39603 | 2-Acetylthiophene | Others |
| 2-Acetylthiophene is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||
| M54508 | Mad1 (6-21) | Others |
| Mad1 (6-21) is the 6-21 fragment of Mad1 protein. | ||
| M58606 | (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide | Wnt/beta-catenin |
| N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide; Macamide Impurity | ||
| (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp). (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. | ||
| M1773 | PI-103 | PI3K |
| PI103 | ||
| PI-103 is a potent, ATP-competitive PI3K,cell-permeable,inhibitor.The IC50 values are 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γrespectively. | ||
| M14852 | PI-103 Hydrochloride | PI3K |
| PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. | ||
| M20833 | Vodobatinib (K0706) | Src-bcr-Abl |
| SCO-088, SUN K706, SUN-K0706 | ||
| Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. | ||
| M24827 | Talacotuzumab | IL Receptor/Related |
| JNJ 56022473; CSL 362 | ||
| Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
